The pro-oncogenic CDK4/6-cyclin D/Rb signaling axis can be targeted by Ribociclib (an oral cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor), which potently attenuates cell proliferation in RCC pre-clinical models [131]. The gene discussed is CDK4; the disease is renal cell carcinoma.